tetano
Editor, Senior Moderator
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
Anne Rechtien[SUP]8[/SUP][SUP],[/SUP][SUP]9[/SUP][SUP],[/SUP]
Correspondence information about the author Anne Rechtien
Email the author Anne Rechtien
, Laura Richert[SUP]8[/SUP]
, Hadrien Lorenzo
, Gloria Martrus
, Boris Hejblum
, Christine Dahlke
, Rahel Kasonta
, Madeleine Zinser
, Hans Stubbe
, Urte Matschl
, Ansgar Lohse
, Verena Kr?hling
, Markus Eickmann
, Stephan Becker
,
VEBCON Consortium
, Rodolphe Thi?baut
, Marcus Altfeld[SUP]8[/SUP]
, Marylyn Addo[SUP]8[/SUP][SUP],[/SUP]
Correspondence information about the author Marylyn AddoEmail the author Marylyn Addo
[SUP]8[/SUP]These authors contributed equally
[SUP]9[/SUP]Lead Contact
Highlights
Summary
Predicting vaccine efficacy remains a challenge. We used a systems vaccinology approach to identify early innate immune correlates of antibody induction in humans receiving the Ebola vaccine rVSV-ZEBOV. Blood samples from days 0, 1, 3, 7, and 14 were analyzed for changes in cytokine levels, innate immune cell subsets, and gene expression. Integrative statistical analyses with cross-validation identified a signature of 5 early innate markers correlating with antibody titers on day 28 and beyond. Among those, IP-10 on day 3 and MFI of CXCR6 on NK cells on day 1 were independent correlates. Consistently, we found an early gene expression signature linked to IP-10. This comprehensive characterization of early innate immune responses to the rVSV-ZEBOV vaccine in humans revealed immune signatures linked to IP-10. These results suggest correlates of vaccine-induced antibody induction and provide a rationale to explore strategies for augmenting the effectiveness of vaccines through manipulation of IP-10.
full article
http://www.cell.com/cell-reports/ful...showall%3Dtrue
Anne Rechtien[SUP]8[/SUP][SUP],[/SUP][SUP]9[/SUP][SUP],[/SUP]
Email the author Anne Rechtien, Laura Richert[SUP]8[/SUP]
, Hadrien Lorenzo
, Gloria Martrus
, Boris Hejblum
, Christine Dahlke
, Rahel Kasonta
, Madeleine Zinser
, Hans Stubbe
, Urte Matschl
, Ansgar Lohse
, Verena Kr?hling
, Markus Eickmann
, Stephan Becker
,
, Rodolphe Thi?baut
, Marcus Altfeld[SUP]8[/SUP]
, Marylyn Addo[SUP]8[/SUP][SUP],[/SUP]
Email the author Marylyn Addo[SUP]8[/SUP]These authors contributed equally
[SUP]9[/SUP]Lead Contact
Highlights
- • 5 early innate markers correlate with antibody response to Ebola vaccine rVSV-ZEBOV
- • IP-10 on day 3 after vaccination is an independent correlate of antibody induction
- • RNA-seq analysis identifies early gene expression signature linked to IP-10
Summary
Predicting vaccine efficacy remains a challenge. We used a systems vaccinology approach to identify early innate immune correlates of antibody induction in humans receiving the Ebola vaccine rVSV-ZEBOV. Blood samples from days 0, 1, 3, 7, and 14 were analyzed for changes in cytokine levels, innate immune cell subsets, and gene expression. Integrative statistical analyses with cross-validation identified a signature of 5 early innate markers correlating with antibody titers on day 28 and beyond. Among those, IP-10 on day 3 and MFI of CXCR6 on NK cells on day 1 were independent correlates. Consistently, we found an early gene expression signature linked to IP-10. This comprehensive characterization of early innate immune responses to the rVSV-ZEBOV vaccine in humans revealed immune signatures linked to IP-10. These results suggest correlates of vaccine-induced antibody induction and provide a rationale to explore strategies for augmenting the effectiveness of vaccines through manipulation of IP-10.
full article
http://www.cell.com/cell-reports/ful...showall%3Dtrue